. 2020 Dec 16;31(23-24):1237–1259. doi: 10.1089/hum.2020.116

Table 3.

I-124 biological half-life of I-124-labeled AAVrh.10 and 9 capsids in selected organs following vector administration

NHP No.^a	Route	Vector Immune Status ^a	AAV Serotype/Transgene ^a	Biological Half-Life, h
NHP No.^a	Route	Vector Immune Status ^a	AAV Serotype/Transgene ^a	Source ^b	Liver	Heart	Vertebrae	Spleen	CSF/Brain	Body
1	Intravenous	Naive	10/mCherry	0.7	71.2	15.0	53.3	20.6	25.7	60.1
1	Intravenous	Immune	10/FXN	0.7	13.1	10.8	19.1	63.0	15.9	24.0
2	Intravenous	Naive	9/mCherry	1.2	22.6	15.6	34.0	22.9	24.8	48.7
2	Intravenous	Immune	9/FXN	0.8	10.1	9.7	13.2	83.5	13.2	22.8
3	Intracisternal	Naive	10/mCherry	13.9	34.7	11.0	34.7	49.5	12.4	43.3
3	Intracisternal	Immune	10/FXN	10.7	22.4	12.9	10.9	15.7	7.7	24.6
4	Intracisternal	Naive	9/mCherry	12.8	66.5	12.6	42.3	55.3	26.7	23.1
4	Intracisternal	Immune	9/FXN	9.6	5.4	5.9	6.1	25.5	7.7	14.1
5	Intracisternal	Naive	9/mCherry	12.5	48.9	23.1	46.2	24.0	4.3	62.8
6	Intracisternal	NaI control	I-124 alone	5.0	14.3	11.3	11.3	13.3	9.9	24.5
6	Intravenous	NaI control	I-124 alone	0.7	12.8	9.3	18.0	8.9	14.7	14.5

The biological half-lives (in h) were calculated from decay constants as T_{1/2 bio} = 0.693/k.

^{^a}

See Table 1 for description of NHP, immune status, and description of the AAV vectors.

^{^b}

Source of I-124 activity is blood for the intravenous route and CSF for the intracisternal route.